Abstract
Gene expression is modulated through the integration of many regulatory elements and their associated transcription factors (TFs). TFs bind to specific DNA sequences and either activate or repress transcriptional activity. Through decades of research, it has been established that aberrant expression or functional abnormalities of TFs can lead to uncontrolled cell division and the development of cancer. Initial studies on transcriptional regulation in cancer have focused on TFs as transcriptional activators. However, recent studies have demonstrated several different mechanisms of transcriptional repression in cancer, which could be potential therapeutic targets for the development of specific anti-cancer agents. In the first section of this review, “Emerging roles of transcriptional repressors in cancer development,” we summarize the current understanding of transcriptional repressors and their involvement in the molecular processes of cancer progression. In the subsequent section, “Therapeutic applications,” we provide an updated overview of the available therapeutic targets for drug discovery and discuss the new frontier of such applications.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abeshouse A, Ahn J, Akbani R, Ally A, Amin S, Andry CD, Annala M, Aprikian A, Armenia J, Arora A (2015) The molecular taxonomy of primary prostate cancer. Cell 163:1011–1025. https://doi.org/10.1016/j.cell.2015.10.025
Ahmad ST, Rogers AD, Chen MJ, Dixit R, Adnani L, Frankiw LS, Lawn SO, Blough MD, Alshehri M, Wu W, Marra MA, Robbins SM, Cairncross JG, Schuurmans C, Chan JA (2019) Capicua regulates neural stem cell proliferation and lineage specification through control of Ets factors. Nat Commun 10:2000–2000. https://doi.org/10.1038/s41467-019-09949-6
Ahn M-Y, Yoon J-H (2017) Histone deacetylase 7 silencing induces apoptosis and autophagy in salivary mucoepidermoid carcinoma cells. J Oral Pathol Med 46:276–283. https://doi.org/10.1111/jop.12560
Aigner K, Dampier B, Descovich L, Mikula M, Sultan A, Schreiber M, Mikulits W, Brabletz T, Strand D, Obrist P, Sommergruber W, Schweifer N, Wernitznig A, Beug H, Foisner R, Eger A (2007) The transcription factor ZEB1 (δEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 26:6979–6988. https://doi.org/10.1038/sj.onc.1210508
An R, Li Y-Q, Lin Y-L, Xu F, Li M-M, Liu Z (2022) EZH1/2 as targets for cancer therapy. Cancer Gene Ther. https://doi.org/10.1038/s41417-022-00555-1
Ashrafizadeh M, Ang HL, Moghadam ER, Mohammadi S, Zarrin V, Hushmandi K, Samarghandian S, Zarrabi A, Najafi M, Mohammadinejad R, Kumar AP (2020) MicroRNAs and their influence on the ZEB family: mechanistic aspects and therapeutic applications in cancer therapy. Biomolecules 10:1040. https://doi.org/10.3390/biom10071040
Avraham S, Korin B, Aviram S, Shechter D, Shaked Y, Aronheim A (2019) ATF3 and JDP2 deficiency in cancer associated fibroblasts promotes tumor growth via SDF-1 transcription. Oncogene 38:3812–3823. https://doi.org/10.1038/s41388-019-0692-y
Banerjee A, Mahata B, Dhir A, Mandal TK, Biswas K (2019) Elevated histone H3 acetylation and loss of the Sp1–HDAC1 complex de-repress the GM2-synthase gene in renal cell carcinoma. J Biol Chem 294:1005–1018. https://doi.org/10.1074/jbc.RA118.004485
Beishline K, Azizkhan-Clifford J (2015) Sp1 and the “hallmarks of cancer.” FEBS J 282:224–258. https://doi.org/10.1111/febs.13148
Beketova E, Fang S, Owens JL, Liu S, Chen X, Zhang Q, Asberry AM, Deng X, Malola J, Huang J (2020) Protein arginine methyltransferase 5 promotes pICln-dependent androgen receptor transcription in castration-resistant prostate cancerPRMT5/pICln promotes AR expression in CRPC. Can Res 80:4904–4917. https://doi.org/10.1158/0008-5472
Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BV, Varambally S (2016) Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med 22:298–305. https://doi.org/10.1038/nm.4045
Bhagwat AS, Vakoc CR (2015) Targeting transcription factors in cancer. Trends Cancer 1:53–65
Bitton-Worms K, Pikarsky E, Aronheim A (2010) The AP-1 repressor protein, JDP2, potentiates hepatocellular carcinoma in mice. Mol Cancer 9:54. https://doi.org/10.1186/1476-4598-9-54
Blattler A, Farnham PJ (2013) Cross-talk between site-specific transcription factors and DNA methylation states. J Biol Chem 288:34287–34294. https://doi.org/10.1074/jbc.R113.512517
Borgoni S, Sofyalı E, Soleimani M, Wilhelm H, Müller-Decker K, Will R, Noronha A, Beumers L, Verschure PJ, Yarden Y, Magnani L, Van Kampen AHC, Moerland PD, Wiemann S (2020) Time-resolved profiling reveals ATF3 as a novel mediator of endocrine resistance in breast cancer. Cancers 12:2918. https://doi.org/10.3390/cancers12102918
Bose R, Karthaus WR, Armenia J, Abida W, Iaquinta PJ, Zhang Z, Wongvipat J, Wasmuth EV, Shah N, Sullivan PS (2017) ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis. Nature 546:671–675. https://doi.org/10.1038/nature22820
Cannon-Albright LA, Teerlink CC, Stevens J, Huang FW, Sipeky C, Schleutker J, Hernandez R, Facelli J, Agarwal N, Trump DL (2021) A rare variant in ERF (rs144812092) predisposes to prostate and bladder cancers in an extended pedigree. Cancers 13:2399. https://doi.org/10.3390/cancers13102399
Cardenas H, Zhao J, Vieth E, Nephew KP, Matei D (2016) EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells. Oncotarget 7:84453–84467. https://doi.org/10.18632/oncotarget.11497
Caslini C, Hong S, Ban YJ, Chen XS, Ince TA (2019) HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells. Oncogene 38:6599–6614. https://doi.org/10.1038/s41388-019-0897-0
Ceccacci E, Minucci S (2016) Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia. Br J Cancer 114:605–611. https://doi.org/10.1038/bjc.2016.36
Chang Yi S, Jalgaonkar Swati P, Middleton Justin D, Hai T (2017) Stress-inducible gene Atf3 in the noncancer host cells contributes to chemotherapy-exacerbated breast cancer metastasis. Proc Natl Acad Sci 114:E7159–E7168. https://doi.org/10.1073/pnas.1700455114
Chen BP, Liang G, Whelan J, Hai T (1994) ATF3 and ATF3 delta Zip. Transcriptional repression versus activation by alternatively spliced isoforms. J Biol Chem 269:15819–15826. https://doi.org/10.1016/S0021-9258(17)40754-X
Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, Diao L, Wang J, Roybal J, Patel M, Ungewiss C, Peng D, Antonia S, Mediavilla-Varela M, Robertson G, Suraokar M, Welsh JW, Erez B, Wistuba Ii, Chen L, Peng D, Wang S, Ullrich SE, Heymach JV, Kurie JM, Qin FX (2014) Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 5:5241. https://doi.org/10.1038/ncomms6241
Chen J, Wu F-X, Luo H-L, Liu J-J, Luo T, Bai T, Li L-Q, Fan X-H (2016) Berberine upregulates miR-22-3p to suppress hepatocellular carcinoma cell proliferation by targeting Sp1. Am J Transl Res 8:4932–4941
Chen X, Zeng K, Xu M, Hu X, Liu X, Xu T, He B, Pan Y, Sun H, Wang S (2018) SP1-induced lncRNA-ZFAS1 contributes to colorectal cancer progression via the miR-150-5p/VEGFA axis. Cell Death Dis 9:1–18. https://doi.org/10.1038/s41419-018-0962-6
Chen L, Wu X, Xie H, Yao N, Xia Y, Ma G, Qian M, Ge H, Cui Y, Huang Y (2019) ZFP57 suppress proliferation of breast cancer cells through down-regulation of MEST-mediated Wnt/β-catenin signalling pathway. Cell Death Dis 10:1–15. https://doi.org/10.1038/s41419-019-1335-5
Cheng Y, Chang Q, Zheng B, Xu J, Li H, Wang R (2019) LncRNA XIST promotes the epithelial to mesenchymal transition of retinoblastoma via sponging miR-101. Eur J Pharmacol 843:210–216. https://doi.org/10.1016/j.ejphar.2018.11.028
Cho H-J, Oh N, Park J-H, Kim K-S, Kim H-K, Lee E, Hwang S, Kim S-J, Park K-S (2019) ZEB1 collaborates with ELK3 to repress E-cadherin expression in triple-negative breast cancer cells. Mol Cancer Res 17:2257–2266. https://doi.org/10.1158/1541-7786.Mcr-19-0380
Chuang J-Y, Yang W-B, Hsu C-C (2020) Increased activation of HDAC1, 2, and 6, and Sp1 underlies therapeutic resistance and tumor growth in glioblastoma. FASEB J 34:1–1. https://doi.org/10.1096/fasebj.2020.34.s1.02838
Conte R, Valentino A, Di Cristo F, Peluso G, Cerruti P, Di Salle A, Calarco A (2020) Cationic polymer nanoparticles-mediated delivery of miR-124 impairs tumorigenicity of prostate cancer cells. Int J Mol Sci 21(3):869. https://doi.org/10.3390/ijms21030869
Darnell JE Jr (2002) Transcription factors as targets for cancer therapy. Nat Rev Cancer 2:740–749. https://doi.org/10.1038/nrc906
Deng Y-R, Chen X-J, Chen W, Wu L-F, Jiang H-P, Lin D, Wang L-J, Wang W, Guo S-Q (2019) Sp1 contributes to radioresistance of cervical cancer through targeting G2/M cell cycle checkpoint CDK1. Cancer Manag Res 11:5835–5844. https://doi.org/10.2147/CMAR.S200907
Di Caprio R, Ciano M, Montano G, Costanzo P, Cesaro E (2015) KAP1 is a novel substrate for the arginine methyltransferase PRMT5. Biology 4:41–49. https://doi.org/10.3390/biology4010041
Doetzlhofer A, Rotheneder H, Lagger G, Koranda M, Kurtev V, Brosch G, Wintersberger E, Seiser C (1999) Histone deacetylase 1 can repress transcription by binding to Sp1. Mol Cell Biol 19:5504–5511. https://doi.org/10.1128/MCB.19.8.5504
Dong H, Wang W, Mo S, Chen R, Zou K, Han J, Zhang F, Hu J (2018) SP1-induced lncRNA AGAP2-AS1 expression promotes chemoresistance of breast cancer by epigenetic regulation of MyD88. J Exp Clin Cancer Res 37:202. https://doi.org/10.1186/s13046-018-0875-3
Dongre A, Rashidian M, Reinhardt F, Bagnato A, Keckesova Z, Ploegh HL, Weinberg RA (2017) Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas. Cancer Res 77:3982–3989. https://doi.org/10.1158/0008-5472.Can-16-3292
Du X, Tu Y, Liu S, Zhao P, Bao Z, Li C, Li J, Pan M, Ji J (2020) LINC00511 contributes to glioblastoma tumorigenesis and epithelial-mesenchymal transition via LINC00511/miR-524-5p/YB1/ZEB1 positive feedback loop. J Cell Mol Med 24:1474–1487. https://doi.org/10.1111/jcmm.14829
Dynan WS, Tjian R (1983a) Isolation of transcription factors that discriminate between different promoters recognized by RNA polymerase II. Cell 32:669–680. https://doi.org/10.1016/0092-8674(83)90053-3
Dynan WS, Tjian R (1983b) The promoter-specific transcription factor Sp1 binds to upstream sequences in the SV40 early promoter. Cell 35:79–87. https://doi.org/10.1016/0092-8674(83)90210-6
Eckschlager T, Plch J, Stiborova M, Hrabeta J (2017) Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci 18(7):1414. https://doi.org/10.3390/ijms18071414
Eger A, Aigner K, Sonderegger S, Dampier B, Oehler S, Schreiber M, Berx G, Cano A, Beug H, Foisner R (2005) DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 24:2375–2385. https://doi.org/10.1038/sj.onc.1208429
Fan MJ, Zou YH, He PJ, Zhang S, Sun XM, Li CZ (2019) Long non-coding RNA SPRY4-IT1 promotes epithelial-mesenchymal transition of cervical cancer by regulating the miR-101-3p/ZEB1 axis. Biosci Rep. https://doi.org/10.1042/bsr20181339
Feinberg AP, Ohlsson R, Henikoff S (2006) The epigenetic progenitor origin of human cancer. Nat Rev Genet 7:21–33. https://doi.org/10.1038/nrg1748
Feng S, Liu W, Bai X, Pan W, Jia Z, Zhang S, Zhu Y, Tan W (2019) LncRNA-CTS promotes metastasis and epithelial-to-mesenchymal transition through regulating miR-505/ZEB2 axis in cervical cancer. Cancer Lett 465:105–117. https://doi.org/10.1016/j.canlet.2019.09.002
Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong STC, Choi H, El Rayes T, Ryu S, Troeger J, Schwabe RF, Vahdat LT, Altorki NK, Mittal V, Gao D (2015) Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527:472–476. https://doi.org/10.1038/nature15748
Fu X, Zhang P, Yu B (2017) Advances toward LSD1 inhibitors for cancer therapy. Future Med Chem 9:1227–1242. https://doi.org/10.4155/fmc-2017-0068
Fu D, Huang Y, Gao M (2019) Hsa_circ_0057481 promotes laryngeal cancer proliferation and migration by modulating the miR-200c/ZEB1 axis. Int J Clin Exp Pathol 12:4066–4076
Fu D, Wang C, Yu L, Yu R (2021) Induction of ferroptosis by ATF3 elevation alleviates cisplatin resistance in gastric cancer by restraining Nrf2/Keap1/xCT signaling. Cell Mol Biol Lett 26:26. https://doi.org/10.1186/s11658-021-00271-y
Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora VK (2014) Organoid cultures derived from patients with advanced prostate cancer. Cell 159:176–187. https://doi.org/10.1016/j.cell.2014.08.016
Gao S, Liu H, Hou S, Wu L, Yang Z, Shen J, Zhou L, Zheng SS, Jiang B (2018) MiR-489 suppresses tumor growth and invasion by targeting HDAC7 in colorectal cancer. Clin Transl Oncol 20:703–712. https://doi.org/10.1007/s12094-017-1770-7
Gascoyne DM, Long E, Veiga-Fernandes H, De Boer J, Williams O, Seddon B, Coles M, Kioussis D, Brady HJ (2009) The basic leucine zipper transcription factor E4BP4 is essential for natural killer cell development. Nat Immunol 10:1118–1124. https://doi.org/10.1038/ni.1787
Glass CK, Rosenfeld MG (2000) The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14:121–141
Glozak MA, Seto E (2007) Histone deacetylases and cancer. Oncogene 26:5420–5432. https://doi.org/10.1038/sj.onc.1210610
Gong P, Qiao F, Wu H, Cui H, Li Y, Zheng Y, Zhou M, Fan H (2018) LncRNA UCA1 promotes tumor metastasis by inducing miR-203/ZEB2 axis in gastric cancer. Cell Death Dis 9:1158. https://doi.org/10.1038/s41419-018-1170-0
Gong P, Wang Y, Jing Y (2019) Apoptosis induction by histone deacetylase inhibitors in cancer cells: role of Ku70. Int J Mol Sci 20:1601. https://doi.org/10.3390/ijms20071601
Guenzle J, Wolf LJ, Garrelfs NWC, Goeldner JM, Osterberg N, Schindler CR, Saavedra JE, Weyerbrock A (2017) ATF3 reduces migration capacity by regulation of matrix metalloproteinases via NFκB and STAT3 inhibition in glioblastoma. Cell Death Discov 3:17006. https://doi.org/10.1038/cddiscovery.2017.6
Gulati N, Béguelin W, Giulino-Roth L (2018) Enhancer of zeste homolog 2 (EZH2) inhibitors. Leuk Lymphoma 59:1574–1585. https://doi.org/10.1080/10428194.2018.1430795
Guo Q, Cheng K, Wang X, Li X, Yu Y, Hua Y, Yang Z (2020) Expression of HDAC1 and RBBP4 correlate with clinicopathologic characteristics and prognosis in breast cancer. Int J Clin Exp Pathol 13:563–572
Hai T, Wolfgang CD, Marsee DK, Allen AE, Sivaprasad U (1999) ATF3 and stress responses. Gene Expr 7:321–335
Harada Y, Kanehira M, Fujisawa Y, Takata R, Shuin T, Miki T, Fujioka T, Nakamura Y, Katagiri T (2010) Cell-permeable peptide DEPDC1-ZNF224 interferes with transcriptional repression and oncogenicity in bladder cancer CellsDEPDC1 is involved in bladder carcinogenesis. Cancer Res 70:5829–5839. https://doi.org/10.1158/0008-5472.CAN-10-0255
Hashiguchi Y, Kawano S, Goto Y, Yasuda K, Kaneko N, Sakamoto T, Matsubara R, Jinno T, Maruse Y, Tanaka H, Morioka M, Hattori T, Tanaka S, Kiyoshima T, Nakamura S (2018) Tumor-suppressive roles of ΔNp63β-miR-205 axis in epithelial-mesenchymal transition of oral squamous cell carcinoma via targeting ZEB1 and ZEB2. J Cell Physiol 233:6565–6577. https://doi.org/10.1002/jcp.26267
Hasim MS, Nessim C, Villeneuve PJ, Vanderhyden BC, Dimitroulakos J (2018) Activating transcription factor 3 as a novel regulator of chemotherapy response in breast cancer. Transl Oncol 11:988–998. https://doi.org/10.1016/j.tranon.2018.06.001
Hedrick E, Cheng Y, Jin U-H, Kim K, Safe S (2016) Specificity protein (Sp) transcription factors Sp1, Sp3 and Sp4 are non-oncogene addiction genes in cancer cells. Oncotarget 7:22245. https://doi.org/10.18632/oncotarget.7925
Hedrick E, Li X, Safe S (2017) Penfluridol represses integrin expression in breast cancer through induction of reactive oxygen species and downregulation of Sp transcription factors. Mol Cancer Ther 16:205–216. https://doi.org/10.1158/1535-7163.Mct-16-0451
Hu X-T, Xing W, Zhao R-S, Tan Y, Wu X-F, Ao L-Q, Li Z, Yao M-W, Yuan M, Guo W, Li S-Z, Yu J, Ao X, Xu X (2020) HDAC2 inhibits EMT-mediated cancer metastasis by downregulating the long noncoding RNA H19 in colorectal cancer. J Exp Clin Cancer Res 39:270. https://doi.org/10.1186/s13046-020-01783-9
Huang FW, Mosquera JM, Garofalo A, Oh C, Baco M, Amin-Mansour A, Rabasha B, Bahl S, Mullane SA, Robinson BD, Aldubayan S, Khani F, Karir B, Kim E, Chimene-Weiss J, Hofree M, Romanel A, Osborne JR, Kim JW, Azabdaftari G, Woloszynska-Read A, Sfanos K, De Marzo AM, Demichelis F, Gabriel S, Van Allen EM, Mesirov J, Tamayo P, Rubin MA, Powell IJ, Garraway LA (2017) Exome sequencing of African-American prostate cancer reveals loss-of-function ERF mutations. Cancer Discov 7:973–983. https://doi.org/10.1158/2159-8290.CD-16-0960
Huang J-H, Xu Y, Lin F-Y (2020) The inhibition of microRNA-326 by SP1/HDAC1 contributes to proliferation and metastasis of osteosarcoma through promoting SMO expression. J Cell Mol Med 24:10876–10888. https://doi.org/10.1111/jcmm.15716
Huang C, Chen R, Zheng F, Tang Y, Wang X, Chen Z, Lai X (2021) Inhibitory role of ATF3 in gastric cancer progression through regulating cell EMT and stemness. Cancer Cell Int 21:127. https://doi.org/10.1186/s12935-021-01828-9
Hwang JW, Cho Y, Bae G-U, Kim S-N, Kim YK (2021) Protein arginine methyltransferases: promising targets for cancer therapy. Exp Mol Med 53:788–808. https://doi.org/10.1038/s12276-021-00613-y
Injinari N, Amini-Farsani Z, Yadollahi-Farsani M, Teimori H (2021) Apoptotic effects of valproic acid on miR-34a, miR-520h and HDAC1 gene in breast cancer. Life Sci 269:119027. https://doi.org/10.1016/j.lfs.2021.119027
Jiang Y, Jin S, Tan S, Shen Q, Xue Y (2019) MiR-203 acts as a radiosensitizer of gastric cancer cells by directly targeting ZEB1. Onco Targets Ther 12:6093–6104. https://doi.org/10.2147/ott.S197539
Jiang Y, Ji X, Liu K, Shi Y, Wang C, Li Y, Zhang T, He Y, Xiang M, Zhao R (2020) Exosomal miR-200c-3p negatively regulates the migraion and invasion of lipopolysaccharide (LPS)-stimulated colorectal cancer (CRC). BMC Mol Cell Biol 21:48. https://doi.org/10.1186/s12860-020-00291-0
Jiao Y, Zhu G, Yu J, Li Y, Wu M, Zhao J, Tian X (2019) miR-1271 inhibits growth, invasion and epithelial-mesenchymal transition by targeting ZEB1 in ovarian cancer cells. Onco Targets Ther 12:6973–6980. https://doi.org/10.2147/ott.S219018
Jing P, Zhao N, Ye M, Zhang Y, Zhang Z, Sun J, Wang Z, Zhang J, Gu Z (2018) Protein arginine methyltransferase 5 promotes lung cancer metastasis via the epigenetic regulation of miR-99 family/FGFR3 signaling. Cancer Lett 427:38–48. https://doi.org/10.1016/j.canlet.2018.04.019
Karthik IP, Desai P, Sukumar S, Dimitrijevic A, Rajalingam K, Mahalingam S (2018) E4BP4/NFIL3 modulates the epigenetically repressed RAS effector RASSF8 function through histone methyltransferases. J Biol Chem 293:5624–5635. https://doi.org/10.1074/jbc.RA117.000623
Kashiwada M, Levy DM, Mckeag L, Murray K, Schröder AJ, Canfield SM, Traver G, Rothman PB (2010) IL-4-induced transcription factor NFIL3/E4BP4 controls IgE class switching. Proc Natl Acad Sci 107:821–826. https://doi.org/10.1073/pnas.0909235107
Katoch A, Jamwal VL, Faheem MM, Kumar S, Senapati S, Yadav G, Gandhi SG, Goswami A (2021) Overlapping targets exist between the Par-4 and miR-200c axis which regulate EMT and proliferation of pancreatic cancer cells. Transl Oncol 14:100879. https://doi.org/10.1016/j.tranon.2020.100879
Katz S, Heinrich R, Aronheim A (2001) The AP-1 repressor, JDP2, is a bona fide substrate for the c-Jun N-terminal kinase. FEBS Lett 506:196–200. https://doi.org/10.1016/S0014-5793(01)02907-6
Kawamura-Saito M, Yamazaki Y, Kaneko K, Kawaguchi N, Kanda H, Mukai H, Gotoh T, Motoi T, Fukayama M, Aburatani H, Takizawa T, Nakamura T (2006) Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation. Hum Mol Genet 15:2125–2137. https://doi.org/10.1093/hmg/ddl136
Kilian M, Friedrich M, Sanghvi K, Green E, Pusch S, Kawauchi D, Löwer M, Sonner JK, Krämer C, Zaman J, Jung S, Breckwoldt MO, Willimksy G, Eichmüller SB, Von Deimling A, Wick W, Sahm F, Platten M, Bunse L (2022) T-cell receptor therapy targeting mutant capicua transcriptional repressor in experimental gliomas. Clin Cancer Res 28:378–389. https://doi.org/10.1158/1078-0432.Ccr-21-1881
Kim H, Ze’ev AR (2020) PRMT5 function and targeting in cancer. Cell Stress 4:199. https://doi.org/10.15698/cst2020.08.228
Kim HS, Sohn H, Jang SW, Lee GR (2019) The transcription factor NFIL3 controls regulatory T-cell function and stability. Exp Mol Med 51:1–15. https://doi.org/10.1038/s12276-019-0280-9
Kim JW, Ponce RK, Okimoto RA (2021) Capicua in human cancer. Trends Cancer 7:77–86. https://doi.org/10.1016/j.trecan.2020.08.010
Krebs AM, Mitschke J, Lasierra Losada M, Schmalhofer O, Boerries M, Busch H, Boettcher M, Mougiakakos D, Reichardt W, Bronsert P, Brunton VG, Pilarsky C, Winkler TH, Brabletz S, Stemmler MP, Brabletz T (2017) The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat Cell Biol 19:518–529. https://doi.org/10.1038/ncb3513
Ku HC, Cheng CF (2020) Master regulator Activating Transcription Factor 3 (ATF3) in metabolic homeostasis and cancer. Front Endocrinol 11:556. https://doi.org/10.3389/fendo.2020.00556
Kumar A, Coleman I, Morrissey C, Zhang X, True LD, Gulati R, Etzioni R, Bolouri H, Montgomery B, White T (2016) Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med 22:369–378. https://doi.org/10.1038/nm.4053
Lang R, Patel D, Morris JJ, Rutschman RL, Murray PJ (2002) Shaping gene expression in activated and resting primary macrophages by IL-101. J Immunol 169:2253–2263. https://doi.org/10.4049/jimmunol.169.5.2253
Lehmann W, Mossmann D, Kleemann J, Mock K, Meisinger C, Brummer T, Herr R, Brabletz S, Stemmler MP, Brabletz T (2016) ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types. Nat Commun 7:10498. https://doi.org/10.1038/ncomms10498
Lei Y, Liu L, Zhang S, Guo S, Li X, Wang J, Su B, Fang Y, Chen X, Ke H, Tao W (2017) Hdac7 promotes lung tumorigenesis by inhibiting Stat3 activation. Mol Cancer 16:170. https://doi.org/10.1186/s12943-017-0736-2
Lemercier C, Brocard M-P, Puvion-Dutilleul F, Kao H-Y, Albagli O, Khochbin S (2002) Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor. J Biol Chem 277:22045–22052. https://doi.org/10.1074/jbc.M201736200
Li J, Xia L, Zhou Z, Zuo Z, Xu C, Song H, Cai J (2018) MiR-186-5p upregulation inhibits proliferation, metastasis and epithelial-to-mesenchymal transition of colorectal cancer cell by targeting ZEB1. Arch Biochem Biophys 640:53–60. https://doi.org/10.1016/j.abb.2018.01.002
Li L, Sun R-M, Jiang G-Q (2020) ATF3 demethylation promotes the transcription of ARL4C, which acts as a tumor suppressor in human breast cancer. Onco Targets Ther 13:3467. https://doi.org/10.2147/OTT.S243632
Lin C-L, Tsai M-L, Lin C-Y, Hsu K-W, Hsieh W-S, Chi W-M, Huang L-C, Lee C-H (2019) HDAC1 and HDAC2 double knockout triggers cell apoptosis in advanced thyroid cancer. Int J Mol Sci 20:454. https://doi.org/10.3390/ijms20020454
Lin YH, Guo L, Yan F, Dou ZQ, Yu Q, Chen G (2020a) Long non-coding RNA HOTAIRM1 promotes proliferation and inhibits apoptosis of glioma cells by regulating the miR-873-5p/ZEB2 axis. Chin Med J 133:174–182. https://doi.org/10.1097/cm9.0000000000000615
Lin YK, Wu W, Ponce RK, Kim JW, Okimoto RA (2020b) Negative MAPK-ERK regulation sustains CIC-DUX4 oncoprotein expression in undifferentiated sarcoma. Proc Natl Acad Sci 117:20776–20784. https://doi.org/10.1073/pnas.2009137117
Liu X, Yu Y, Zhang J, Lu C, Wang L, Liu P, Song H (2018a) HDAC1 silencing in ovarian cancer enhances the chemotherapy response. Cell Physiol Biochem 48:1505–1518. https://doi.org/10.1159/000492260
Liu Y, Du Y, Hu X, Zhao L, Xia W (2018b) Up-regulation of ceRNA TINCR by SP1 contributes to tumorigenesis in breast cancer. BMC Cancer 18:367. https://doi.org/10.1186/s12885-018-4255-3
Liu L, Jiang H, Pan H, Zhu X (2021) LncRNA XIST promotes liver cancer progression by acting as a molecular sponge of miR-200b-3p to regulate ZEB1/2 expression. J Int Med Res 49:3000605211016211. https://doi.org/10.1177/03000605211016211
Lv T, Song K, Zhang L, Li W, Chen Y, Diao Y, Yao Q, Liu P (2018) miRNA-34a decreases ovarian cancer cell proliferation and chemoresistance by targeting HDAC1. Biochem Cell Biol 96:663–671. https://doi.org/10.1139/bcb-2018-0031
Male V, Nisoli I, Gascoyne DM, Brady HJM (2012) E4BP4: an unexpected player in the immune response. Trends Immunol 33:98–102. https://doi.org/10.1016/j.it.2011.10.002
Mansour MR, He S, Li Z, Lobbardi R, Abraham BJ, Hug C, Rahman S, Leon TE, Kuang Y-Y, Zimmerman MW, Blonquist T, Gjini E, Gutierrez A, Tang Q, Garcia-Perez L, Pike-Overzet K, Anders L, Berezovskaya A, Zhou Y, Zon LI, Neuberg D, Fielding AK, Staal FJT, Langenau DM, Sanda T, Young RA, Look AT (2018) JDP2: an oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia. J Exp Med 215:1929–1945. https://doi.org/10.1084/jem.20170484
Mémin E, Yehia G, Razavi R, Molina CA (2002) ICER reverses tumorigenesis of rat prostate tumor cells without affecting cell growth. Prostate 53:225–231. https://doi.org/10.1002/pros.10149
Mioduszewska B, Jaworski J, Szklarczyk AW, Klejman A, Kaczmarek L (2008) Inducible cAMP early repressor (ICER)-evoked delayed neuronal death in the organotypic hippocampal culture. J Neurosci Res 86:61–70. https://doi.org/10.1002/jnr.21469
Molina CA, Foulkes NS, Lalli E, Sassone-Corsi P (1993) Inducibility and negative autoregulation of CREM: an alternative promoter directs the expression of ICER, an early response repressor. Cell 75:875–886. https://doi.org/10.1016/0092-8674(93)90532-U
Nie D, Shan X, Nie L, Duan Y, Chen Z, Yang Y, Li Z, Tian L, Gao Q, Shan Y, Tang N (2016) Hepatitis C virus core protein interacts with Snail and histone deacetylases to promote the metastasis of hepatocellular carcinoma. Oncogene 35:3626–3635. https://doi.org/10.1038/onc.2015.428
Nieto MA, Huang Ruby Y-J, Jackson Rebecca A, Thiery Jean P (2016) EMT: 2016. Cell 166:21–45. https://doi.org/10.1016/j.cell.2016.06.028
Noh JH, Bae HJ, Eun JW, Shen Q, Park SJ, Kim HS, Nam B, Shin WC, Lee EK, Lee K (2014) HDAC2 provides a critical support to malignant progression of hepatocellular carcinoma through feedback control of mTORC1 and AKT. Can Res 74:1728–1738. https://doi.org/10.1158/0008-5472.CAN-13-2109
Noman MZ, Janji B, Abdou A, Hasmim M, Terry S, Tan TZ, Mami-Chouaib F, Thiery JP, Chouaib S (2017) The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200. OncoImmunology 6:e1263412. https://doi.org/10.1080/2162402X.2016.1263412
Noori J, Sharifi M, Haghjooy Javanmard S (2018) miR-30a inhibits melanoma tumor metastasis by targeting the E-cadherin and zinc finger E-box binding homeobox 2. Adv Biomed Res 7:143. https://doi.org/10.4103/abr.abr_146_18
Okimoto RA, Breitenbuecher F, Olivas VR, Wu W, Gini B, Hofree M, Asthana S, Hrustanovic G, Flanagan J, Tulpule A (2017) Inactivation of Capicua drives cancer metastasis. Nat Genet 49:87–96. https://doi.org/10.1038/ng.3728
Pal S, Vishwanath SN, Erdjument-Bromage H, Tempst P, Sif S (2004) Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol Cell Biol 24:9630–9645. https://doi.org/10.1128/MCB.24.21.9630-9645.2004
Park SY, Kim MJ, Park SA, Kim JS, Min KN, Kim DK, Lim W, Nam JS, Sheen YY (2015) Combinatorial TGF-β attenuation with paclitaxel inhibits the epithelial-to-mesenchymal transition and breast cancer stem-like cells. Oncotarget 6:37526–37543. https://doi.org/10.18632/oncotarget.6063
Pathi S, Li X, Safe S (2014) Tolfenamic acid inhibits colon cancer cell and tumor growth and induces degradation of specificity protein (Sp) transcription factors. Mol Carcinog 53(Suppl 1):E53-61. https://doi.org/10.1002/mc.22010
Peri A, Conforti B, Baglioni-Peri S, Luciani P, Cioppi F, Buci L, Corbetta S, Ballaré E, Serio M, Spada A (2001) Expression of cyclic adenosine 3′, 5′-monophosphate (cAMP)-responsive element binding protein and inducible-cAMP early repressor genes in growth hormone-secreting pituitary adenomas with or without mutations of the Gsα gene. J Clin Endocrinol Metab 86:2111–2117
Perotti V, Baldassari P, Molla A, Nicolini G, Bersani I, Grazia G, Benigni F, Maurichi A, Santinami M, Anichini A, Mortarini R (2019) An actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cells. Oncogene 38:4384–4396. https://doi.org/10.1038/s41388-019-0729-2
Pigazzi M, Ricotti E, Germano G, Faggian D, Aricò M, Basso G (2007) cAMP response element binding protein (CREB) overexpression in childhood acute lymphoblastic and myeloid leukemia. Haematologica 92:1435–1437. https://doi.org/10.3324/haematol.11122
Pigazzi M, Manara E, Baron E, Basso G (2008) ICER expression inhibits leukemia phenotype and controls tumor progression. Leukemia 22:2217–2225. https://doi.org/10.1038/leu.2008.244
Piu F, Aronheim A, Katz S, Karin M (2001) AP-1 repressor protein JDP-2: inhibition of UV-mediated apoptosis through p53 down-regulation. Mol Cell Biol 21:3012–3024. https://doi.org/10.1128/mcb.21.9.3012-3024.2001
Polychronopoulos S, Verykokakis M, Yazicioglu MN, Sakarellos-Daitsiotis M, Cobb MH, Mavrothalassitis G (2006) The transcriptional ETS2 repressor factor associates with active and inactive Erks through distinct FXF motifs. J Biol Chem 281:25601–25611. https://doi.org/10.1074/jbc.M605185200
Postigo AA, Depp JL, Taylor JJ, Kroll KL (2003) Regulation of Smad signaling through a differential recruitment of coactivators and corepressors by ZEB proteins. EMBO J 22:2453–2462. https://doi.org/10.1093/emboj/cdg226
Qian Y, Arellano G, Ifergan I, Lin J, Snowden C, Kim T, Thomas JJ, Law C, Guan T, Balabanov RD, Kaech SM, Miller SD, Choi J (2021) ZEB1 promotes pathogenic Th1 and Th17 cell differentiation in multiple sclerosis. Cell Reports 36:109602. https://doi.org/10.1016/j.celrep.2021.109602
Qu J, Li M, An J, Zhao B, Zhong W, Gu Q, Cao L, Yang H, Hu C (2015) MicroRNA-33b inhibits lung adenocarcinoma cell growth, invasion, and epithelial-mesenchymal transition by suppressing Wnt/β-catenin/ZEB1 signaling. Int J Oncol 47:2141–2152. https://doi.org/10.3892/ijo.2015.3187
Ramaiah MJ, Tangutur AD, Manyam RR (2021) Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy. Life Sci 277:119504. https://doi.org/10.1016/j.lfs.2021.119504
Rana Z, Diermeier S, Hanif M, Rosengren RJ (2020) Understanding failure and improving treatment using HDAC inhibitors for prostate cancer. Biomedicines 8:22. https://doi.org/10.3390/biomedicines8020022
Rawat A, Gopisetty G, Thangarajan R (2014) E4BP4 is a repressor of epigenetically regulated SOSTDC1 expression in breast cancer cells. Cell Oncol 37:409–419. https://doi.org/10.1007/s13402-014-0204-6
Reynolds N, O’shaughnessy A, Hendrich B (2013) Transcriptional repressors: multifaceted regulators of gene expression. Development 140:505–512. https://doi.org/10.1242/dev.083105
Režen T, Zmrzljak UP, Bensa T, Tomaš TC, Cirnski K, Stojan J, Rozman D (2020) Novel insights into biological roles of inducible cAMP early repressor ICER. Biochem Biophys Res Commun 530:396–401. https://doi.org/10.1016/j.bbrc.2020.05.017
Rhodes LV, Tate CR, Segar HC, Burks HE, Phamduy TB, Hoang V, Elliott S, Gilliam D, Pounder FN, Anbalagan M, Chrisey DB, Rowan BG, Burow ME, Collins-Burow BM (2014) Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. Breast Cancer Res Treat 145:593–604. https://doi.org/10.1007/s10549-014-2979-6
Richard G, Dalle S, Monet M-A, Ligier M, Boespflug A, Pommier RM, De La Fouchardière A, Perier-Muzet M, Depaepe L, Barnault R, Tondeur G, Ansieau S, Thomas E, Bertolotto C, Ballotti R, Mourah S, Battistella M, Lebbé C, Thomas L, Puisieux A, Caramel J (2016) ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors. EMBO Mol Med 8:1143–1161. https://doi.org/10.15252/emmm.201505971
Robinson D, Van Allen EM, Wu Y-M, Schultz N, Lonigro RJ, Mosquera J-M, Montgomery B, Taplin M-E, Pritchard CC, Attard G (2015) Integrative clinical genomics of advanced prostate cancer. Cell 161:1215–1228. https://doi.org/10.1016/j.cell.2015.05.001
Ropero S, Esteller M (2007) The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 1:19–25. https://doi.org/10.1016/j.molonc.2007.01.001
Safe S, Abdelrahim M (2005) Sp transcription factor family and its role in cancer. Eur J Cancer 41:2438–2448
Safe S, Abbruzzese J, Abdelrahim M, Hedrick E (2018) Specificity protein transcription factors and cancer: opportunities for drug development. Cancer Prev Res 11:371–382. https://doi.org/10.1158/1940-6207.CAPR-17-0407
Santoro F, Botrugno OA, Dal Zuffo R, Pallavicini I, Matthews GM, Cluse L, Barozzi I, Senese S, Fornasari L, Moretti S (2013) A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Blood J Am Soc Hematol 121:3459–3468. https://doi.org/10.1182/blood-2012-10-461988
Sapio L, Salzillo A, Ragone A, Illiano M, Spina A, Naviglio S (2020) Targeting CREB in cancer therapy: a key candidate or one of many? An update. Cancers 12:3166. https://doi.org/10.3390/cancers12113166
Sementchenko VI, Watson DK (2000) Ets target genes: past, present and future. Oncogene 19:6533–6548
Shao Q, Wang Q, Wang J (2019) LncRNA SCAMP1 regulates ZEB1/JUN and autophagy to promote pediatric renal cell carcinoma under oxidative stress via miR-429. Biomed Pharmacother 120:109460. https://doi.org/10.1016/j.biopha.2019.109460
Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA, Shi Y (2004) Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119:941–953
Singh BN, Zhang G, Hwa YL, Li J, Dowdy SC, Jiang S-W (2010) Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther 10:935–954. https://doi.org/10.1586/era.10.62
Sizemore GM, Pitarresi JR, Balakrishnan S, Ostrowski MC (2017) The ETS family of oncogenic transcription factors in solid tumours. Nat Rev Cancer 17:337–351. https://doi.org/10.1038/nrc.2017.20
Sobocińska J, Molenda S, Machnik M, Oleksiewicz U (2021) KRAB-ZFP transcriptional regulators acting as oncogenes and tumor suppressors: an overview. Int J Mol Sci 22:2212. https://doi.org/10.3390/ijms22042212
Subramanian S, Bates SE, Wright JJ, Espinoza-Delgado I, Piekarz RL (2010) Clinical toxicities of histone deacetylase inhibitors. Pharmaceuticals 3:2751–2767. https://doi.org/10.1158/1078-0432
Sun S, Hang T, Zhang B, Zhu L, Wu Y, Lv X, Huang Q, Yao H (2019) miRNA-708 functions as a tumor suppressor in colorectal cancer by targeting ZEB1 through Akt/mTOR signaling pathway. Am J Transl Res 11:5338–5356
Sun J, Piao J, Li N, Yang Y, Kim KY, Lin Z (2020) Valproic acid targets HDAC1/2 and HDAC1/PTEN/Akt signalling to inhibit cell proliferation via the induction of autophagy in gastric cancer. Febs j 287:2118–2133. https://doi.org/10.1111/febs.15122
Sun M, Ju J, Ding Y, Zhao C, Tian C (2022) The signaling pathways regulated by KRAB zinc-finger proteins in cancer. Biochimica et Biophysica Acta 1877:188731. https://doi.org/10.1016/j.bbcan.2022.188731
Taki M, Abiko K, Baba T, Hamanishi J, Yamaguchi K, Murakami R, Yamanoi K, Horikawa N, Hosoe Y, Nakamura E, Sugiyama A, Mandai M, Konishi I, Matsumura N (2018) Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation. Nat Commun 9:1685. https://doi.org/10.1038/s41467-018-03966-7
Tarighat SS, Santhanam R, Frankhouser D, Radomska HS, Lai H, Anghelina M, Wang H, Huang X, Alinari L, Walker A (2016) The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation. Leukemia 30:789–799. https://doi.org/10.1038/leu.2015.308
Thompson MR, Xu D, Williams BRG (2009) ATF3 transcription factor and its emerging roles in immunity and cancer. J Mol Med 87:1053. https://doi.org/10.1007/s00109-009-0520-x
Tong Z, Cai M, Wang X, Kong L, Mai S, Liu Y, Zhang H, Liao Y, Zheng F, Zhu W (2012) EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin. Oncogene 31:583–594. https://doi.org/10.1038/onc.2011.254
Vellingiri B, Iyer M, Devi Subramaniam M, Jayaramayya K, Siama Z, Giridharan B, Narayanasamy A, Abdal Dayem A, Cho S-G (2020) Understanding the role of the transcription factor Sp1 in ovarian cancer: from theory to practice. Int J Mol Sci 21:1153. https://doi.org/10.3390/ijms21031153
Wade PA, Pruss D, Wolffe AP (1997) Histone acetylation: chromatin in action. Trends Biochem Sci 22:128–132. https://doi.org/10.1016/s0968-0004(97)01016-5
Wang J, Lee S, Teh CE-Y, Bunting K, Ma L, Shannon MF (2009) The transcription repressor, ZEB1, cooperates with CtBP2 and HDAC1 to suppress IL-2 gene activation in T cells. Int Immunol 21:227–235. https://doi.org/10.1093/intimm/dxn143
Wang T, Wang XG, Xu JH, Wu XP, Qiu HL, Yi H, Li WX (2012) Overexpression of the human ZNF300 gene enhances growth and metastasis of cancer cells through activating NF-kB pathway. J Cell Mol Med 16:1134–1145. https://doi.org/10.1111/j.1582-4934.2011.01388.x
Wang J, Ye Q, Cao Y, Guo Y, Huang X, Mi W, Liu S, Wang C, Yang H-S, Zhou BP, Evers BM, She Q-B (2017) Snail determines the therapeutic response to mTOR kinase inhibitors by transcriptional repression of 4E-BP1. Nat Commun 8:2207–2207. https://doi.org/10.1038/s41467-017-02243-3
Wang Q-M, Tang PM-K, Lian G-Y, Li C, Li J, Huang X-R, To K-F, Lan H-Y (2018) Enhanced cancer immunotherapy with Smad3-silenced NK-92 cells. Cancer Immunol Res 6:965–977. https://doi.org/10.1158/2326-6066.Cir-17-0491
Wei L, He Y, Bi S, Li X, Zhang J, Zhang S (2021) miRNA-199b-3p suppresses growth and progression of ovarian cancer via the CHK1/E-cadherin/EMT signaling pathway by targeting ZEB1. Oncol Rep 45:569–581. https://doi.org/10.3892/or.2020.7895
Weissmann S, Cloos PA, Sidoli S, Jensen ON, Pollard S, Helin K (2018) The tumor suppressor CIC directly regulates MAPK pathway genes via histone deacetylation. Cancer Res 78:4114–4125. https://doi.org/10.1158/0008-5472.Can-18-0342
Witt AE, Lee CW, Lee TI, Azzam DJ, Wang B, Caslini C, Petrocca F, Grosso J, Jones M, Cohick EB, Gropper AB, Wahlestedt C, Richardson AL, Shiekhattar R, Young RA, Ince TA (2017) Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer. Oncogene 36:1707–1720. https://doi.org/10.1038/onc.2016.337
Wong D, Yip S (2020) Making heads or tails - the emergence of capicua (CIC) as an important multifunctional tumour suppressor. J Pathol 250:532–540. https://doi.org/10.1002/path.5400
Xiao Y, Xiang T, Luo X, Li C, Li Q, Peng W, Li L, Li S, Wang Z, Tang L (2014) Zinc-finger protein 545 inhibits cell proliferation as a tumor suppressor through inducing apoptosis and is disrupted by promoter methylation in breast cancer. PLoS ONE 9:e110990
Yang J, Tian B, Sun H, Garofalo RP, Brasier AR (2017a) Epigenetic silencing of IRF1 dysregulates type III interferon responses to respiratory virus infection in epithelial to mesenchymal transition. Nat Microbiol 2:17086. https://doi.org/10.1038/nmicrobiol.2017.86
Yang R, Chen LH, Hansen LJ, Carpenter AB, Moure CJ, Liu H, Pirozzi CJ, Diplas BH, Waitkus MS, Greer PK, Zhu H, Mclendon RE, Bigner DD, He Y, Yan H (2017b) Cic loss promotes gliomagenesis via aberrant neural stem cell proliferation and differentiation. Can Res 77:6097–6108. https://doi.org/10.1158/0008-5472.Can-17-1018
Yang W, Yang S, Zhang M, Gao D, He T, Guo M (2017c) ZNF545 suppresses human hepatocellular carcinoma growth by inhibiting NF-kB signaling. Genes Cancer 8:528. https://doi.org/10.18632/genesandcancer.137
Yang C, Sun J, Liu W, Yang Y, Chu Z, Yang T, Gui Y, Wang D (2019) Long noncoding RNA HCP5 contributes to epithelial-mesenchymal transition in colorectal cancer through ZEB1 activation and interacting with miR-139-5p. Am J Transl Res 11:953–963
Ye X, Tam WL, Shibue T, Kaygusuz Y, Reinhardt F, Ng Eaton E, Weinberg RA (2015) Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature 525:256–260. https://doi.org/10.1038/nature14897
Yoe J, Kim D, Kim S, Lee Y (2020) Capicua restricts cancer stem cell-like properties in breast cancer cells. Oncogene 39:3489–3506. https://doi.org/10.1038/s41388-020-1230-7
Yoshiya S, Itoh S, Yoshizumi T, Yugawa K, Kurihara T, Toshima T, Harada N, Hashisako M, Yonemasu H, Fukuzawa K, Oda Y, Mori M (2021) Impact of capicua on pancreatic cancer progression. Ann Surg Oncol 28:3198–3207. https://doi.org/10.1245/s10434-020-09339-z
Yu Y, Cao F, Yu X, Zhou P, Di Q, Lei J, Tai Y, Wu H, Li X, Wang X, Zhang W, Li P, Li Y (2017) The expression of HDAC7 in cancerous gastric tissues is positively associated with distant metastasis and poor patient prognosis. Clin Transl Oncol 19:1045–1054. https://doi.org/10.1007/s12094-017-1639-9
Yu S, Wang D, Shao Y, Zhang T, Xie H, Jiang X, Deng Q, Jiao Y, Yang J, Cai C, Sun L (2019a) SP1-induced lncRNA TINCR overexpression contributes to colorectal cancer progression by sponging miR-7-5p. Aging 11:1389–1403. https://doi.org/10.18632/aging.101839
Yu W, Deng W, Zhao Q, Zhuang H, Zhang C, Jian Z (2019b) miR-501 acts as an independent prognostic factor that promotes the epithelial–mesenchymal transition through targeting JDP2 in hepatocellular carcinoma. Hum Cell 32:343–351. https://doi.org/10.1007/s13577-019-00243-7
Zhai X, Li L-S, Zhou Y-D, Ji W-Y, Chen H, Xiao H, Liang P (2021) EZH2 regulates the malignancy of human glioblastoma cells via modulation of Twist mRNA stability. Eur J Pharmacol 904:174177. https://doi.org/10.1016/j.ejphar.2021.174177
Zhang C, Xiang T, Li S, Ye L, Feng Y, Pei L, Li L, Wang X, Sun R, Ren G (2018) The novel 19q13 KRAB zinc-finger tumour suppressor ZNF382 is frequently methylated in oesophageal squamous cell carcinoma and antagonises Wnt/β-catenin signalling. Cell Death Dis 9:1–15. https://doi.org/10.1038/s41419-018-0604-z
Zhang Q, Mao Z, Sun J (2019a) NF-κB inhibitor, BAY11-7082, suppresses M2 tumor-associated macrophage induced EMT potential via miR-30a/NF-κB/Snail signaling in bladder cancer cells. Gene 710:91–97. https://doi.org/10.1016/j.gene.2019.04.039
Zhang WY, Liu QH, Wang TJ, Zhao J, Cheng XH, Wang JS (2019b) CircZFR serves as a prognostic marker to promote bladder cancer progression by regulating miR-377/ZEB2 signaling. Biosci Rep 39:2779. https://doi.org/10.1042/bsr2019b2779
Zhang Y, Xu L, Li A, Han X (2019c) The roles of ZEB1 in tumorigenic progression and epigenetic modifications. Biomed Pharmacother 110:400–408. https://doi.org/10.1016/j.biopha.2018.11.112
Zhang J, Wencker M, Marliac Q, Berton A, Hasan U, Schneider R, Laubreton D, Cherrier DE, Mathieu A-L, Rey A, Jiang W, Caramel J, Genestier L, Marçais A, Marvel J, Ghavi-Helm Y, Walzer T (2021) Zeb1 represses TCR signaling, promotes the proliferation of T cell progenitors and is essential for NK1.1+ T cell development. Cell Mol Immunol 18:2140–2152. https://doi.org/10.1038/s41423-020-0459-y
Zhou B, Zheng P, Li Z, Li H, Wang X, Shi Z, Han Q (2018a) CircPCNXL2 sponges miR-153 to promote the proliferation and invasion of renal cancer cells through upregulating ZEB2. Cell Cycle 17:2644–2654. https://doi.org/10.1080/15384101.2018.1553354
Zhou Q, Chen J, Feng J, Wang J (2018b) E4BP4 promotes thyroid cancer proliferation by modulating iron homeostasis through repression of hepcidin. Cell Death Dis 9:987. https://doi.org/10.1038/s41419-018-1001-3
Zhu Y, He D, Bo H, Liu Z, Xiao M, Xiang L, Zhou J, Liu Y, Liu X, Gong L, Ma Y, Zhou Y, Zhou M, Xiong W, Yang F, Xing X, Li R, Li W, Cao K (2019) The MRVI1-AS1/ATF3 signaling loop sensitizes nasopharyngeal cancer cells to paclitaxel by regulating the Hippo–TAZ pathway. Oncogene 38:6065–6081. https://doi.org/10.1038/s41388-019-0858-7
Zhuang W, Li Z, Dong X, Zhao N, Liu Y, Wang C, Chen J (2019) Schisandrin B inhibits TGF-β1-induced epithelial-mesenchymal transition in human A549 cells through epigenetic silencing of ZEB1. Exp Lung Res 45:157–166. https://doi.org/10.1080/01902148.2019.1631906
Zou Q, Zhou E, Xu F, Zhang D, Yi W, Yao J (2018) A TP73-AS1/miR-200a/ZEB1 regulating loop promotes breast cancer cell invasion and migration. J Cell Biochem 119:2189–2199. https://doi.org/10.1002/jcb.26380
Acknowledgements
This research was supported by the 2022 Scientific Promotion Program funded by Jeju National University.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Park, M., Kang, K.W. & Kim, J.W. The role and application of transcriptional repressors in cancer treatment. Arch. Pharm. Res. 46, 1–17 (2023). https://doi.org/10.1007/s12272-023-01427-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-023-01427-4